Drake Plastics announces the formation of Drake Plastics Medical to better serve the specialized requirements of the medical device and life science industries. Drake Plastics Medical will match the innovative processing expertise, for which Drake Plastics has been recognized, with a quality management system that meets the requirements of ISO 13485. Drake Plastics Medical is currently ISO 9001-2008.
Drake Plastics Medical will enhance the performance and reliability of our customers' products by:
- • Utilizing in-house extrusion, molding and machining combined with material knowledge to help customers select the right material and process from concept through production
- • Reducing barriers, both in cost and time, to convert specialty medical grade polymers in usable forms accelerating the introduction of new products
- • Producing and certifying to the quality systems and standards expected by medical customers
Key Management will be comprised of Steve Quance, President, Mike Oliveto, Commercial Director and Kathy Oliveto, Medical Business Unit Manager, who will be responsible for the daily operations of Drake Plastics Medical. Drake's longtime relationship with Solvay Specialty Polymers makes this a natural extension given Solvay's commitment to the Healthcare market according to Kathy Oliveto. "Our initial focus is to convert Solvay's KetaSpire, Zeniva, AvaSpire, Veriva, Radel and Eviva resins into shapes and parts. Additionally, IXEF PARA shapes for prototyping single use devices will be available from Drake Medical."
Drake Plastics Medical is organized to be a "one-stop shop" supplying small quantities of specialty polymers for prototyping to higher volumes of parts made via machining or injection molding. Drake also stocks shapes made from Victrex 450CA30, 450FC30 and 450FE20 - all FDA compliant resins well suited for non-implant medical and life science applications. Drake's polymer process development resources will also convert custom formulations providing customers' strictly confidential conversion services for new products without the capital expense and time to do so in-house.
Source : finance.yahoo.com